Formycon AG (FSB: FYB, Prime Standard) announced it will publish its financial results for the 2025 fiscal year on April 22, 2026. The Management Board, including CEO Dr. Stefan Glombitza and CFO Enno Spillner, will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call scheduled for the same day at 3:00 PM CEST. The call will be broadcast live in English, and participants can register at https://webcast.meetyoo.de/reg/lNibT8TVWubG. After registration, a confirmation email with individual dial-in data will be sent. The presentation and audio broadcast will be accessible via https://www.webcast-eqs.com/formycon-2025-fy. Following a brief presentation, the Management Board will be available for analysts' questions. The call will be recorded and later available on Formycon's website at https://www.formycon.com/en/investor-relations/publications/.
In the second quarter of 2026, Formycon representatives will attend several investor conferences. On May 11–12, CFO Enno Spillner will present at the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, the company will publish its first quarter 2026 results, followed by a conference call and webcast with the entire Management Board. From June 2–4, CFO Spillner will attend the Jefferies Global Healthcare Conference in New York City. On June 8, the Management Board will participate in the mwb research Roundtable via webcast. The Annual General Meeting is scheduled for June 10 at Haus der Bayerischen Wirtschaft in Munich, Germany. Finally, on June 18, CFO Spillner will attend the UBS Life Sciences Conference in London, UK. A full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
Formycon is a leading independent developer of high-quality biosimilars, focusing on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers the value chain from technical development through clinical trials to regulatory approval. For commercialization, Formycon relies on strong global partnerships. With FYB201/ranibizumab and FYB202/ustekinumab already on the market, and FYB203/aflibercept approved by the FDA, EMA, and MHRA, the company has four pipeline candidates in development, including FYB208/dupilumab. These biosimilars aim to increase patient access to effective and affordable medicines while reducing healthcare costs. Global biosimilar sales currently amount to around $21 billion, with analysts projecting a rise to over $74 billion by 2030.
